Canakinumab for the Treatment of Postprandial Hypoglycemia
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this randomized trial is to test whether a treatment with
canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric
surgery, that is if it improves health related quality of life (mentally or physically) or
reduces the risk of hypoglycemic events.